Rhumbline Advisers boosted its holdings in Intellia Therapeutics Inc (NASDAQ:NTLA) by 60.0% in the fourth quarter, Holdings Channel reports. The firm owned 48,131 shares of the company’s stock after purchasing an additional 18,050 shares during the period. Rhumbline Advisers’ holdings in Intellia Therapeutics were worth $657,000 as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in NTLA. First Trust Advisors LP lifted its holdings in Intellia Therapeutics by 53.4% during the 3rd quarter. First Trust Advisors LP now owns 160,303 shares of the company’s stock worth $4,588,000 after buying an additional 55,798 shares during the last quarter. Candriam Luxembourg S.C.A. lifted its holdings in Intellia Therapeutics by 20.4% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 120,000 shares of the company’s stock worth $3,434,000 after buying an additional 20,300 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Intellia Therapeutics by 6.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 131,051 shares of the company’s stock worth $3,751,000 after buying an additional 7,557 shares during the last quarter. BlackRock Inc. lifted its holdings in Intellia Therapeutics by 7.4% during the 3rd quarter. BlackRock Inc. now owns 2,744,397 shares of the company’s stock worth $78,545,000 after buying an additional 188,098 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in Intellia Therapeutics during the 3rd quarter worth approximately $1,236,000. 72.70% of the stock is currently owned by institutional investors.
In other Intellia Therapeutics news, EVP Andrew Schiermeier bought 7,500 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were purchased at an average cost of $15.72 per share, for a total transaction of $117,900.00. Following the transaction, the executive vice president now directly owns 3,250 shares in the company, valued at $51,090. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.20% of the stock is owned by company insiders.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Wednesday, February 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.11. The business had revenue of $7.90 million for the quarter, compared to the consensus estimate of $9.92 million. Intellia Therapeutics had a negative return on equity of 30.59% and a negative net margin of 280.42%. The business’s revenue was up 17.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.61) EPS. On average, analysts forecast that Intellia Therapeutics Inc will post -2.59 earnings per share for the current year.
A number of research analysts have commented on NTLA shares. BTIG Research started coverage on Intellia Therapeutics in a report on Thursday, February 7th. They set a “buy” rating and a $20.00 target price on the stock. Leerink Swann initiated coverage on Intellia Therapeutics in a report on Tuesday, November 27th. They set an “outperform” rating and a $23.00 target price on the stock. BidaskClub raised Intellia Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 2nd. Chardan Capital reissued a “buy” rating and issued a $57.50 price target on shares of Intellia Therapeutics in a report on Wednesday, February 27th. Finally, Zacks Investment Research downgraded Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th. Eight investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $29.08.
Intellia Therapeutics Profile
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
See Also: Intrinsic Value
Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics Inc (NASDAQ:NTLA).
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.